

=> b reg
 FILE 'REGISTRY' ENTERED AT 10:27:31 ON 24 AUG 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2007 HIGHEST RN 945525-31-5
 DICTIONARY FILE UPDATES: 23 AUG 2007 HIGHEST RN 945525-31-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l13
 L2 STR



VAR G1=C/N
 VAR G2=C/O
 REP G3=(2-3) A
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
 L10 6149 SEA FILE=REGISTRY ABB=ON PLU=ON (6-6-14 OR 6-6-15)/SZ
 L13 34 SEA FILE=REGISTRY SUB=L10 SSS FUL L2

100.0% PROCESSED 4161 ITERATIONS 34 ANSWERS
 SEARCH TIME: 00.00.01

=> b uspatall
 FILE 'USPATFULL' ENTERED AT 10:27:38 ON 24 AUG 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:27:38 ON 24 AUG 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitr 116 tot

L16 ANSWER 1 OF 1 USPATFULL on STN

AN 2007:43085 USPATFULL

TI Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease

IN Coburn, Craig A., Royersford, PA, UNITED STATES

Stachel, Shawn J., Perkasi, PA, UNITED STATES

Vacca, Joseph P., Telford, NJ, UNITED STATES

PI US-20070037784 A1 20070215

AI 2004US-000568153 A1 20040810 (10)

2004WO-US00025791 20040810

20060213 PCT 371 date

PRAI 2003US-000495667P 20030814 (60)

DT Utility

FS APPLICATION

LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 859

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of formula I which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 847157-12-4P 847157-13-5P 847157-14-6P

847157-15-7P 847157-16-8P 847157-17-9P

847157-18-0P 847157-19-1P 847157-20-4P

847157-21-5P 847157-22-6P 847157-23-7P

847157-24-8P 847157-25-9P 847157-26-0P

847157-28-2P 847157-30-6P 847157-31-7P

847157-32-8P 847157-33-9P 847157-34-0P

847157-35-1P 847157-36-2P 847157-37-3P

847157-38-4P 847157-39-5P 847157-40-8P

847157-41-9P 847157-42-0P 847157-43-1P

847157-44-2P 847157-45-3P 847157-46-4P

847225-40-5P

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)


IT 847157-12-4P

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

RN 847157-12-4 USPATFULL

CN Hexanamide, 2-[[[(4S)-17-[methyl(methylsulfonyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl]methyl]amino]-N-(2-methylpropyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b hcap

FILE 'HCAPLUS' ENTERED AT 10:27:54 ON 24 AUG 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2007 VOL 147 ISS 10
 FILE LAST UPDATED: 23 Aug 2007 (20070823/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr l17 1-2


L17 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1149497 HCAPLUS
 DN 146:19371
 TI Macrocyclic Inhibitors of β -Secretase: Functional Activity in an Animal Model. [Erratum to document cited in CA145:465146]
 AU Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Wu, Guoxin; Crouthamel, Michelle; Pietrak, Beth L.; Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan; Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria; Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.
 CS Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems and Structural Biology, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Journal of Medicinal Chemistry (2006), 49(24), 7252
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Guoxin Wu and Michelle Crouthamel were inadvertently omitted from the author list. Their affiliation is the Department of Biol. Chemical, represented by the double dagger symbol in the paper. The correct author list is given.
 IT 847157-19-1P 847157-32-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (macrocyclic inhibitors of β -secretase and functional activity in an animal model (Erratum))
 RN 847157-19-1 HCAPLUS
 CN Hexanamide, N-(2-methylpropyl)-2-[[[(4S)-17-[(methylsulfonyl)propylamino]-2-oxo-3-azatricyclo[13.3.1.1^{6,10}]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl)methylamino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847157-32-8 HCAPLUS
 CN Butanamide, 2-[[[(4S)-17-[methyl(methylsulfonyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl]methyl]amino]-N-(2-methylpropyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:908572 HCAPLUS
 DN 145:465146
 TI Macrocyclic Inhibitors of β -Secretase: Functional Activity in an Animal Model
 AU Stachel, Shawn J.; Coburn, Craig A.; Sankaranarayanan, Sethu; Price, Eric A.; Pietrak, Beth L.; Huang, Qian; Lineberger, Janet; Espeseth, Amy S.; Jin, Lixia; Ellis, Joan; Holloway, M. Katharine; Munshi, Sanjeev; Allison, Timothy; Hazuda, Daria; Simon, Adam J.; Graham, Samuel L.; Vacca, Joseph P.
 CS Department of Medicinal Chemistry, Biological Chemistry, Molecular Systems and Structural Biology, Merck Research Laboratories, West Point, PA, 19486, USA
 SO Journal of Medicinal Chemistry (2006), 49(21), 6147-6150
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 145:465146
 AB A macrocyclic inhibitor of β -secretase was designed by covalently crosslinking the P1 and P3 side chains of an isophthalamide-based inhibitor. Macrocyclization resulted in significantly improved potency and phys. properties when compared to the initial lead structures. More importantly, these macrocyclic inhibitors also displayed in vivo amyloid lowering when dosed in a murine model.
 IT 847157-19-1P 847157-32-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (macrocyclic inhibitors of β -secretase and functional activity in an animal model)
 RN 847157-19-1 HCAPLUS
 CN Hexanamide, N-(2-methylpropyl)-2-[[[(4S)-17-[(methylsulfonyl)propylamino]-2-oxo-3-azatricyclo[13.3.1.16,10]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl]methyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847157-32-8 HCAPLUS

CN Butanamide, 2-[[[(4S)-17-[methyl(methylsulfonyl)amino]-2-oxo-3-azatricyclo[13.3.1.16,10]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl)methyl]amino]-N-(2-methylpropyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitrm fhitr 117 3

L17 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:177829 HCAPLUS

DN 142:280070

TI Preparation of macrocyclic β -secretase inhibitors for the treatment of Alzheimer's disease

IN Coburn, Craig; Stachel, Shawn J.; Vacca, Joseph P.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005018545	A2	20050303	2004WO-US25791	20040810
	WO2005018545	A3	20050519		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2004266605	A1	20050303	2004AU-0266605	20040810
CA---	2535337	A1	20050303	2004CA-2535337	20040810
EP---	1656359	A2	20060517	2004EP-0780598	20040810
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

CN---	1835936	A	20060920	CN 2004-80023327	20040810
JP	2007502278	T	20070208	2006JP-0523290	20040810
IN	2006DN00522	A	20070810	2006IN-DN00522	20060131
US	2007037784	A1	20070215	2006US-0568153	20060213
PRAI	2003US-495667P	P	20030814		
	2004WO-US25791	W	20040810		
OS	CASREACT 142:280070; MARPAT 142:280070				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Macrocytic compds. of formula I [R1 = H, R4-S(O)pN(R5), CN, etc.; R2, R3 = H, alkyl, halo, OH, alkoxy, etc.; R4 = alkyl, (substituted) NH2, Ph, benzyl, etc.; R5 = H, alkyl, Ph, benzyl; p = 0-2; X = CH2, O] are prepared which are inhibitors of the β -secretase enzyme and that are useful in the treatment or prevention of diseases such as Alzheimer's disease. The invention is also directed to pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which the β -secretase enzyme is involved. Thus, II was prepared from Me 3-nitrobenzoate, allyltributyl stannane, m-allyltyrosine Me ester hydrochloride and N-isobutyl-L-norleucineamide hydrochloride in several steps. The compds. had IC50 from about 1 nM to 1 μ M against β -secretase enzyme.

IT 847157-12-4P 847157-13-5P 847157-14-6P
847157-15-7P 847157-16-8P 847157-17-9P
847157-18-0P 847157-19-1P 847157-20-4P
847157-21-5P 847157-22-6P 847157-23-7P
847157-24-8P 847157-25-9P 847157-26-0P
847157-28-2P 847157-30-6P 847157-31-7P
847157-32-8P 847157-33-9P 847157-34-0P
847157-35-1P 847157-36-2P 847157-37-3P
847157-38-4P 847157-39-5P 847157-40-8P
847157-41-9P 847157-42-0P 847157-43-1P
847157-44-2P 847157-45-3P 847157-46-4P
847225-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

IT 847157-12-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of macrocyclic β -secretase inhibitors for treatment of Alzheimer's disease)

RN 847157-12-4 HCAPLUS

CN Hexanamide, 2-[[[(4S)-17-[methyl(methylsulfonyl)amino]-2-oxo-3-azatricyclo[13.3.1.1^{6,10}]eicosa-1(19),6,8,10(20),15,17-hexaen-4-yl]methyl]amino]-N-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:48:31 ON 24 AUG 2007)

FILE 'REGISTRY' ENTERED AT 09:48:46 ON 24 AUG 2007

L1 STR
L2 STR L1
L3 0 L2

FILE 'HCAPLUS' ENTERED AT 10:12:40 ON 24 AUG 2007

L4 1 US20070037784/PN

FILE 'REGISTRY' ENTERED AT 10:13:03 ON 24 AUG 2007

FILE 'HCAPLUS' ENTERED AT 10:13:03 ON 24 AUG 2007
L5 TRA L4 1- RN : 63 TERMS

FILE 'REGISTRY' ENTERED AT 10:13:03 ON 24 AUG 2007

L6 63 SEA L5
L7 STR L2
L8 0 L7
L9 STR L7
L10 6149 (6-6-14 OR 6-6-15)/SZ
L11 1 L2 SAM SUB=L10
L12 38 L10 AND L6
L13 34 L2 FULL SUB=L10
L14 34 L13 AND L6

FILE 'HCAOLD' ENTERED AT 10:24:18 ON 24 AUG 2007

L15 0 L13

FILE 'USPATFULL, USPAT2' ENTERED AT 10:24:24 ON 24 AUG 2007

L16 1 L13

FILE 'HCAPLUS' ENTERED AT 10:24:38 ON 24 AUG 2007

L17 3 L13

FILE 'BIOSIS' ENTERED AT 10:25:41 ON 24 AUG 2007

L18 0 L13

FILE 'MEDLINE' ENTERED AT 10:25:49 ON 24 AUG 2007

L19 0 L13

FILE 'EMBASE' ENTERED AT 10:26:18 ON 24 AUG 2007

L20 0 L13

=>